Belgium· BE-AMP-SAM594364-00
Atgam 50 mg/ml
A antilymphocyte immunoglobulin (horse) product containing anti-t lymphocyte equine immunoglobulin for human use, registered in Belgium by Pfizer. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Antilymphocyte immunoglobulin (horse) is registered in 9 of 19 countries.
Countries holding a registration under ATC L04AA03 (antilymphocyte immunoglobulin (horse)), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Antilymphocyte immunoglobulin (horse) · ATC L04AA03
9 / 19 countries
- Belgiumprice
- Canada
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Anti-T Lymphocyte Equine Immunoglobulin for Human Use
- Manufacturer
- Pfizer
- Country
- Belgium (BE)
- ATC code
- L04AA03
- ATC class
- Antilymphocyte immunoglobulin (horse)
- Defined daily dose
- 1.05 g, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L04AA03
Antilymphocyte immunoglobulin (horse), as other registers publish it.
- FinlandAtgamPfizer Oy
- SwitzerlandAtgam
- NorwayAtgamPFIZER AS
- DenmarkAtgamPfizer ApS
- PolandAtgamPfizer Europe MA EEIG
- CanadaATGAMPFIZER CANADA ULC
- NetherlandsAtgam 50 mg/ml concentraat voor oplossing voor infusiePfizer B.V.
- IrelandAtgam 50 mg/ml concentrate for solution for infusionPfizer Healthcare Ireland Unlimited Company
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4f3d34ef-c916-42c7-8cd5-8bad2d883c4b GET /v1/drugs/4f3d34ef-c916-42c7-8cd5-8bad2d883c4b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "REVOKED",
"name_en": "Atgam 50 mg/ml",
"name_fr": "Atgam 50 mg/ml",
"name_nl": "Atgam 50 mg/ml",
"amp_code": "SAM594364-00",
"strengths": [
"50.0000",
"50.0000"
],
"pack_count": 1,
"substances": [
"Anti-T Lymphocyte Equine Immunoglobulin for Human Use",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Antilymphocyte Immunoglobulin (Horse)",
"authorisation_numbers": [
"BE594364"
]
}See everything about antilymphocyte immunoglobulin (horse).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.